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A BS TR AC T
BACKGROUND
Hypophosphatasia results from mutations in the gene for the tissue-nonspecific iso-
zyme of alkaline phosphatase (TNSALP). Inorganic pyrophosphate accumulates 
extracellularly, leading to rickets or osteomalacia. Severely affected babies often die 
from respiratory insufficiency due to progressive chest deformity or have persistent 
bone disease. There is no approved medical therapy. ENB-0040 is a bone-targeted, 
recombinant human TNSALP that prevents the manifestations of hypophosphatasia 
in Tnsalp knockout mice.
METHODS
We enrolled infants and young children with life-threatening or debilitating perinatal 
or infantile hypophosphatasia in a multinational, open-label study of treatment with 
ENB-0040. The primary objective was the healing of rickets, as assessed by means of 
radiographic scales. Motor and cognitive development, respiratory function, and safety 
were evaluated, as well as the pharmacokinetics and pharmacodynamics of ENB-0040.
RESULTS
Of the 11 patients recruited, 10 completed 6 months of therapy; 9 completed 1 year. 
Healing of rickets at 6 months in 9 patients was accompanied by improvement in 
developmental milestones and pulmonary function. Elevated plasma levels of the 
TNSALP substrates inorganic pyrophosphate and pyridoxal 5′-phosphate diminished. 
Increases in serum parathyroid hormone accompanied skeletal healing, often neces-
sitating dietary calcium supplementation. There was no evidence of hypocalcemia, 
ectopic calcification, or definite drug-related serious adverse events. Low titers of 
anti–ENB-0040 antibodies developed in four patients, with no evident clinical, bio-
chemical, or autoimmune abnormalities at 48 weeks of treatment.
CONCLUSIONS
ENB-0040, an enzyme-replacement therapy, was associated with improved findings on 
skeletal radiographs and improved pulmonary and physical function in infants and 
young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma 
and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.)
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Hypophosphatasia is the inborn er-ror of metabolism that is characterized by low serum alkaline-phosphatase activ-
ity from loss-of-function mutations, typically mis-
sense, within the gene for the tissue-nonspecific 
isozyme of alkaline phosphatase (TNSALP).1 Nat-
ural substrates of TNSALP that accumulate in hy-
pophosphatasia include inorganic pyrophosphate,2 
an inhibitor of mineralization,3 and pyridoxal 
5′-phosphate (PLP), the principal circulating form 
of vitamin B6.4 High extracellular levels of inor-
ganic pyrophosphate block hydroxyapatite crystal 
growth3,5 and cause rickets or osteomalacia. Hy-
percalcemia and hyperphosphatemia can develop 
in severely affected patients.1 The deranged vi-
tamin B6 metabolism shows that TNSALP func-
tions as a cell-surface enzyme6 and explains why 
pyridoxine-responsive seizures may occur when 
TNSALP deficiency is profound.7
The manifestations of hypophosphatasia range 
from neonatal death with almost no skeletal min-
eralization to dental problems in adults without 
any bone symptoms.1,5 Such differences in expres-
sion are explained partly by autosomal recessive 
and autosomal dominant patterns of inheri-
tance.1 From a clinical nosology based on the pa-
tient’s age when skeletal disease first develops,8 
autosomal recessive inheritance explains all peri-
natal cases and nearly all infantile cases of hy-
pophosphatasia.9-11 Perinatal hypophosphatasia is 
characterized by extreme skeletal hypomineraliza-
tion, and survival is rare.1,12 Infantile hypophos-
phatasia develops before 6 months of age with 
rickets, failure to thrive, hypotonia, and myopa-
thy and is often complicated by hypercalcemia, 
nephrocalcinosis, epilepsy, and craniosynosto-
sis.7,13-18 Deciduous teeth are lost because insuf-
ficient cementum links them to the periodontal 
ligament.19 Although spontaneous improvement 
sometimes occurs in infantile hypophosphata-
sia,20 substantial bone disease and weakness 
often persist.1,5 Skeletal deterioration typically 
results in death from respiratory insufficiency.14-17
Attempts to treat patients with infantile hypo-
phosphatasia by administering intravenous infu-
sions of plasma enriched in soluble alkaline phos-
phatase from patients with Paget’s disease14,15 or 
alkaline phosphatase purified from human pla-
centas21 have been unsuccessful, suggesting that 
skeletal mineralization requires the presence of 
TNSALP on osteoblasts, chondrocytes, and matrix 
vesicles.5,22,23 There is no approved medical treat-
ment for hypophosphatasia.
ENB-0040 (asfotase alfa; Enobia Pharma) is 
an investigational, recombinant, fusion protein 
comprising the TNSALP ectodomain, the con-
stant region of the human IgG1 Fc domain, and 
a terminal deca-aspartate motif for bone target-
ing.24 In Tnsalp knockout mice, which constitute 
an animal model of infantile hypophosphata-
sia,25 treatment with daily subcutaneous injec-
tions of ENB-0040 at doses that result in serum 
levels ranging from 650 to 1000 U per liter pre-
serve the mineralization of bones and teeth.24,26,27 
A phase 1 study involving adult patients with hypo-
phosphatasia showed peak and trough ENB-0040 
levels in this range after one intravenous dose of 
3 mg per kilogram of body weight and weekly 
subcutaneous doses of 2 mg per kilogram.28 We 
conducted a clinical trial of treatment with ENB-
0040 for at least 1 year in infants and young 
children with life-threatening hypophosphatasia.
ME THODS
STUDY DESIGN AND PATIENTS
In an open-label study, we evaluated the safety, 
tolerability, bioavailability, pharmacokinetics,29 
pharmacodynamics, and efficacy of treatment with 
ENB-0040. Efficacy assessments included skeletal 
changes, as evaluated by means of radiography, and 
gross motor, fine motor, and cognitive develop-
ment, as measured with the Bayley Scales of Infant 
and Toddler Development, third edition (Bayley-III), 
a norm-referenced instrument used to assess de-
velopmental functioning of children from 1 to 42 
months of age and to identify children with de-
velopmental delay. Raw scores of successfully com-
pleted items are converted to scaled and composite 
scores allowing comparison with children in a 
standardized sample. Developmental age-equiva-
lent scores in months allow raw-score compari-
sons with typically developing children.30 All pa-
tients were to receive ENB-0040 for 6 months and 
then have the opportunity to enroll in an open-
label extension study.
Eligibility criteria were an age of 3 years or 
less, symptoms of hypophosphatasia occurring 
before the age of 6 months, hypophosphatasemia, 
an elevated plasma PLP level, hypophosphatasia-
related skeletal disease as assessed radiographi-
cally, failure to thrive, rachitic chest deformity or 
pyridoxine-responsive seizures, and nontraumatic 
or poorly healing fractures, hypercalcemia, cranio-
synostosis, nephrocalcinosis, or respiratory com-
promise from hypophosphatasia. Patients were 
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excluded if they had a major coexisting disease, 
a treatable form of rickets, previous exposure to 
bisphosphonates, hypocalcemia or hypophospha-
temia, or a serum 25-hydroxyvitamin D level of 
less than 20 ng per milliliter (50 nM) or if they 
had received another experimental treatment for 
hypophosphatasia (e.g., bone marrow transplan-
tation).16,17
STUDY OVERSIGHT
The study design was developed through a collabo-
ration between the sponsor, Enobia Pharma, and 
the authors. The protocol was approved by the 
local institutional review boards, and written in-
formed consent was obtained from the patients’ 
parents. Safety and efficacy were monitored quar-
terly and on an ad hoc basis by an independent 
data and safety monitoring board. The primary 
statistical analyses were performed by Statistics 
Collaborative. Other organizations involved in the 
management and analysis of study data are listed 
in the Methods section in the Supplementary Ap-
pendix (available with the full text of this article 
at NEJM.org). All the authors evaluated the study 
findings, made the decision to submit the manu-
script for publication, and vouch for the complete-
ness and accuracy of the reported data and the 
fidelity of the study to the protocol. The first author 
wrote the first draft of the manuscript, and the 
other authors aided in its revision. The study proto-
col, including the statistical analysis plan, is avail-
able at NEJM.org.
STUDY TREATMENT
Patients received ENB-0040 (at a concentration of 
40 mg per milliliter) as a single intravenous infu-
Table 1. Characteristics of the Patients at Baseline.*
Characteristic Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Form of hypophosphatasia Perinatal Infantile Infantile Infantile Perinatal
Age — mo 7.5 6 33 18 36
Sex Female Female Female Female Female
TNSALP genotype c.881A>C p.D294A 
c.547G>A 
p.D183H†
c.407G>A p.Arg136His 
c.1133A>T 
p.Asp378Val‡
c.658G>A p.Gly220Arg 
c.659G>C 
p.Gly220Ala§
c.1077C>G p.Ile359Met 
c.1133A>T 
p.Asp378Val‡
c.98C>T p.A33V 
c.98C>T  
p.A33V†
Serum ALP (normal range) 
— U/liter¶
20 (117–352) 8 (<390) 33 (108–317) 58 (80–425) 19 (79–267)
Plasma PLP — × ULN 10 5 4 >3 2
Severity of rickets‖ Severe Severe Extremely severe Severe Moderate
Respiratory status CPAP Progressive respiratory 
deterioration
Tracheostomy and  
ventilation
Tracheostomy and  
ventilation
Supplemental oxygen 
by nasal cannula
Failure to thrive Yes Yes Yes Yes Yes
Nephrocalcinosis Yes Yes Yes Yes No
Gross motor function — 
age-equivalent in mo**
<1 No data — too fragile 
to test
<1 <1 7
Feeding Tube Tube Tube Tube Oral
*  ALP denotes alkaline phosphatase, CPAP continuous positive airway pressure, PLP pyridoxal 5′-phosphate, TNSALP tissue-nonspecific iso-
zyme of alkaline phosphatase, and ULN upper limit of the normal range.
†  TNSALP mutation analysis was performed by Centre d’Etudes de Biologie Prénatale, Université de Versailles (Versailles, France).
‡  TNSALP mutation analysis was performed by Connective Tissue Gene Tests (Allentown, PA).
§  TNSALP mutation analysis was performed by Steven Mumm, Ph.D., of the Washington University School of Medicine (St. Louis).
¶  The normal range is for the center where the patient was treated.
‖  Extremely severe rickets was defined as the partial or complete absence of visible bones on radiographs, severe rickets as a near absence 
of metaphyseal features with large radiolucent “tongues” and sclerosis, and moderate rickets as rachitic changes (metaphyseal flaring and 
fraying, widening of physes, areas of subphyseal demineralization, and bowing).
** Gross motor function was assessed with the use of the Bayley Scales of Infant and Toddler Development, third edition (Bayley-III), a 
norm-referenced instrument used to assess developmental functioning of children from 1 to 42 months of age and to identify children 
with developmental delay. Raw scores of successfully completed items are converted to scaled and composite scores allowing comparison 
with children in a standardized sample. Developmental age-equivalent scores in months allow raw-score comparisons with typically devel-
oping children.30
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sion at a dose of 2 mg per kilogram, followed by 
subcutaneous injections three times per week at a 
dose of 1 mg per kilogram. The subcutaneous dose 
could be increased up to 3 mg per kilogram if there 
was worsening failure to thrive, deteriorating pul-
monary function, or no radiographic evidence of 
skeletal improvement.
STATISTICAL ANALYSIS
The primary efficacy end point was a change in 
the skeletal manifestations of hypophosphatasia, 
including rickets, as assessed on radiography. Two 
methods of assessment were used. First, three ra-
diologists rated changes from baseline to week 
48 using a 7-point scale (radiographic global im-
pression of change [RGI-C]), which is based on 
ratings of the characteristics of severe hypophos-
phatasia (including irregularity of the provisional 
zone of calcification; physeal widening; metaphy-
seal flaring, fraying, radiolucencies, and patchy os-
teosclerosis; altered ratio of mid-diaphyseal cortex-
to-bone thickness; gracile bones; absence of some 
or all bones; and recent fractures). A reduction of 
3 points represented severe worsening, and an in-
crease of 3 points indicated complete healing of the 
skeletal disease. For each patient, the mean score 
among the radiologists was used for analysis, with 
a response to treatment defined as a mean increase 
of 2 or more points (i.e., substantial healing). 
The proportion of patients with a response, with 
the 95% exact confidence interval, was calculated 
at weeks 24 and 48.31 Two-sided Wilcoxon signed-
rank tests32 were used to determine whether the 
median scores differed from 0 (i.e., no change).
Second, a single reader rated the growth-plate 
abnormalities at the wrists and knees, using a 
10-point rickets-severity scale (RSS),33 with higher 
scores representing more severe rickets. All radio-
graphs were rated with masking of sequence and 
patient identifiers. Changes from baseline were 
calculated at weeks 24 and 48, with the use of 
Wilcoxon signed-rank tests to determine whether 
median changes differed from 0 (see the Supple-
mentary Appendix).
Additional efficacy studies included evaluations 
of respiratory status and motor and cognitive func-
tion. Bone biopsy and densitometry were precluded 
by the small size of the patients and their precari-
ous clinical status.
R ESULT S
CHARACTERISTICS OF THE PATIENTS
A total of 11 patients, 7 girls and 4 boys, were en-
rolled between October 2008 and December 2009; 
they ranged in age at baseline from 2 weeks to 
3 years (Table 1). Five patients had perinatal hypo-
phosphatasia, and six had infantile hypophos-
Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 Patient 11
Perinatal Perinatal Infantile Infantile Perinatal Infantile
0.6 1 30 6 2 4
Male Male Male Female Female Male
c.119C>T p.Ala40Val 
c.1231A>G 
p.Thr411Ala‡
c.215T>C p.Ile72Thr 
c.881A>C 
p.Asp294Ala‡
c.212G>A p.Arg71His 
c.571G>A 
p.Gly191Lys†
c.212G>A p.R71H 
c.571G>A  
p.E191K†
c.920C>T p.P307L 
c.1171C>T 
p.R391C‡
c.350A>G p.Tyr117Cys 
c.1001G>A 
p.Gly334Asp‡
21 (73–266) 20 (73–266) 42 (76–308) 23 (59–425) 6 (32–91) 93 (143–320)
17 8 18 14 Receiving pyridoxine 3
Extremely severe Severe Moderate Severe Severe Severe
Endotracheal intuba-
tion and ventilation
Progressive respiratory 
deterioration
Ambient air Progressive respiratory 
deterioration
Progressive respiratory 
deterioration
Progressive respiratory 
deterioration
Yes Yes Yes Yes Yes Yes
Yes Kidney stones No Yes Yes Yes
No data — too fragile 
to test
<1 9 <1 1 <1
Tube Tube Oral Tube Oral Oral
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phatasia. All had symptoms before the age of 
6 months, including failure to thrive, fractures, 
and substantial motor delay or regression. Patients 
with erupted teeth had lost dentition. All but two 
patients had nephrocalcinosis or renal stones. The 
infants received calcium-restricted formulas (with 
the use of feeding tubes) for hypercalcemia, and 
vitamin D supplementation, if it was being admin-
istered, was continued. All had hypophosphatas-
emia. Levels of plasma PLP were 2 to 18 times the 
upper limit of the normal range in 10 patients, 
with a higher level in the 1 patient who received 
pyridoxine for vitamin B6–responsive seizures. 
One patient was homozygous for a TNSALP mis-
sense mutation. The others were compound het-
erozygotes of 18 additional TNSALP missense mu-
tations (Table 1). The case summaries, laboratory 
findings, and radiographic changes are provided 
in the Supplementary Appendix.
Treatment Findings
Consent for treatment was withdrawn for 1 of the 
11 patients because of irritability, oxygen desatu-
ration, rigors, and low-grade fever during receipt 
of the intravenous dose. The other 10 patients com-
pleted 6 months of treatment and entered the ex-
tension study. One patient died from sepsis after 
7.5 months of therapy. Nine patients are current-
ly participating in the extension study, with an 
average treatment duration of 18 months (range, 
12 to 26) (see the Supplementary Appendix).
Immediately after the intravenous infusion, the 
serum ENB-0040 level was as high as 14,200 U per 
liter (normal range for TNSALP, approximately 
100 to 400). After the patients received the subcu-
taneous dose of 1 mg per kilogram three times per 
week, trough activity averaged 580 U per liter, and 
with higher doses (i.e., subcutaneous injections of 
up to 3 mg per kilogram three times per week), 
values in or near the anticipated range of efficacy 
were observed in all patients (see the Results 
section in the Supplementary Appendix).24,26 The 
weight-normalized model and the allometric (body 
size) model29 fit the data similarly. However, the 
allometric model provided the better fit for the 
data, showing a bioavailability of ENB-0040 of 
72% and an estimated half-life of approximately 
5 days.
PRIMARY END POINT
Baseline radiographs in all patients showed hypo-
phosphatasia-associated skeletal disease. Skeletal 
healing became apparent as early as week 3 in Pa-
tient 2 and was striking at week 24 (Fig. 1 and 2) 
in all patients except Patient 3, who had no visible 
bone at baseline. No skeletal deterioration was ob-
served, except in Patient 4, whose consent for treat-
A B
E
Baseline Week 24 Week 48C
D Baseline Week 24 Week 48F
Figure 1. Radiographic Findings at Baseline and at Weeks 24 and 48 
in Patient 2.
A radiograph obtained at baseline shows that the right radius and ulna me-
taphyses are flared and contain only focal, irregular calcification (Panel A). At 
week 24, these metaphyses are mineralized, with distinct provisional zones 
of calcification, and the metacarpals have wider widths and better-defined 
cortexes and no longer have lytic areas at their bases (Panel B). At week 48, 
the radius and ulna have better modeling (Panel C). The striking rickets in-
volving the left lower limb in the baseline radiograph (Panel D) shows 
marked improvement at week 24 but with a modeling defect featuring an 
expanded distal femur (Panel E), which is improved at week 48 (Panel F).
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on May 18, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Enzyme-Replacement Ther apy in Life-Threatening Hypophosphatasia
n engl j med 366;10 nejm.org march 8, 2012 909
ment was withdrawn during the intravenous in-
fusion and who subsequently had marked skeletal 
demineralization (Fig. 3). Improvements in skel-
etal quality included diffusely increased mineral 
content, corrected or improved endochondral and 
membranous bone formation, fracture mending, 
reduced deformity, resolution of radiolucencies and 
sclerosis, and extensive modeling and remodeling.
RGI-C scores improved from baseline to week 
24 and from baseline to week 48, with 9 of 10 pa-
tients (90%; 95% confidence interval [CI], 55 to 
100) and 8 of 9 patients (89%; 95% CI, 52 to 100), 
respectively, meeting the criterion for a treatment 
response (see the Results section in the Supple-
mentary Appendix). The patient who died from 
sepsis was judged to have had a response at 24 
weeks. The median RGI-C score was increased by 
2.0 points at week 24 and by 2.3 points at week 
48 (P = 0.004 for both comparisons), indicating 
substantial and continued healing of rickets. Near-
ly all patients with a response had improvement in 
physeal widening, metaphyseal flaring, irregular-
ity of the provisional zone of calcification, and 
metaphyseal radiolucencies. The patient with no 
visible bone at baseline did not have an initial re-
sponse to treatment but did have some remineral-
ization at 48 weeks. The RSS score33 also improved 
significantly. With the exclusion of the patient who 
had no visible bone, the median RSS score at base-
line was 9.5. At weeks 24 and 48, the median score 
was reduced by 3.5 points (in 9 patients, P = 0.004) 
and by 8.8 points (in 8 patients, P = 0.008), respec-
tively (see the Supplementary Appendix).
SECONDARY END POINTS
At baseline, all but 1 patient had gracile or nonvis-
ible ribs on radiographs, accompanied by respira-
tory compromise ranging from progressive insuf-
ficiency to frank ventilatory failure requiring full 
mechanical ventilation (Table 1 and Video 1). Re-
spiratory function tended to decline initially during 
ENB-0040 therapy in the infants who were not re-
ceiving ventilatory support but then improved in all 
patients, along with better mineralization of the rib 
cage (Fig. 2), which was evident as early as week 
12. At week 48, 6 of the 9 patients were breathing 
ambient air without ventilatory support (as com-
pared with 1 of 11 at baseline), 1 was receiving 
supplemental oxygen through a nasal cannula, 
1 was receiving mechanical ventilation only at 
night, and 1 remained on full mechanical venti-
lation (see the Supplementary Appendix).
Performance on the Bayley-III instrument30 was 
assessed at baseline in all but two patients (whose 
medical condition was too fragile) and at weeks 
24 and 48. At baseline, all the patients had gross 
motor delays. None could bear weight through the 
legs owing to skeletal abnormalities and muscle 
weakness, including the four patients who were 
18 months of age or older (Video 2). Improvements 
in age-equivalent scores for gross motor, fine mo-
tor, and cognitive development were noted in seven 
of the eight patients with complete evaluations. Of 
the nine patients who were treated for 48 weeks, 
all but two were bearing weight through the legs; 
four were walking or taking early steps, one was 
standing, two were crawling, and one was sitting 
(Videos 3, 4, and 5). Patient 3, who at baseline had 
no radiographically visible bone, had a tracheos-
tomy, and had no spontaneous movement, moved 
all limbs against gravity at 48 weeks.
A B
D
Baseline Week 24
C Baseline Week 24
Figure 2. Radiographic Findings at Baseline and at Week 24 in Patient 6.
The baseline radiograph shows extreme hypomineralization of the left hand 
(Panel A). Substantial mineralization is apparent at week 24 (Panel B). As 
compared with the findings in the chest at baseline (Panel C), remineraliza-
tion of all ossified structures of the chest (including ribs, clavicles, spine, 
and scapulae) can be seen at week 24 (Panel D).
Videos showing 
patients at 
baseline and 
after therapy 
are available at 
NEJM.org
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Serum parathyroid hormone was at a low-
normal level in 5 of 6 patients at baseline, despite 
dietary calcium restriction, and usually increased 
during treatment, generally together with the ra-
diographic improvements. Dietary calcium restric-
tion was then liberalized for all infants, and for 
some, the intake was increased to a level above 
age-appropriate recommendations to control the 
rise in parathyroid hormone. The level of plasma 
PLP was elevated in all patients at baseline (Table 
1). For the 10 patients who did not receive supple-
mentation with vitamin B6, the median level was 
262 ng per milliliter (1060 nM) at baseline, 46 ng 
per milliliter (186 nM) at 24 weeks, and 23 ng per 
milliliter (93 nM) at 48 weeks (P = 0.004 and 
P = 0.02, respectively). Plasma levels of inorganic 
pyrophosphate were measured before and after 
treatment in five patients; the median level de-
creased from 5.2 nM at baseline to 1.1 and 1.9 nM 
at weeks 24 and 48, respectively (see the Supple-
mentary Appendix).
ADVERSE EVENTS
The most common therapy-related adverse event 
was a reaction at the subcutaneous-injection site, 
consisting of mild, localized, transient erythema. 
There was no evidence of ectopic calcification from 
the treatment, including on funduscopic examina-
tion; nephrocalcinosis did not progress after the 
initial 6 months of treatment and it even improved 
in some patients. Serious adverse events were gen-
erally consistent with severe hypophosphatasia 
(Table 2, and the Supplementary Appendix). Three 
serious adverse events (one case each of respira-
tory distress, craniosynostosis, and conductive 
hearing loss) were considered by the investiga-
tors to be possibly related to the study treatment. 
ENB-0040 did not appear to have an effect on 
craniosynostosis, a progressive complication of 
severe hypophosphatasia,18 and craniectomies 
were performed in two patients.
No important concerns emerged from serum 
chemical or hematologic tests or urinalyses. Serum 
calcium and inorganic-phosphate levels showed 
only transient minor fluctuations, and there were 
no clinical signs of hypocalcemia from calcium-
avid bones (“hungry bones”). There were no 
treatment-related adverse events suggestive of 
hypersensitivity, nor was there evidence of tachy-
phylaxis. During the first 6 months, four of the 
nine patients tested positive for anti–ENB-0040 
antibodies, but titers remained relatively low 
(range, 2 to 128) and did not appear to influence 
clinical outcomes in the follow-up period.
DISCUSSION
Hypophosphatasia is almost always fatal when 
severe skeletal disease is obvious at birth.1,5,12
The prognosis for patients with infantile hypo-
phosphatasia is uncertain at presentation, but 
clinical and skeletal deterioration14-17 or vitamin 
B6–responsive seizures7 indicate a lethal course.
There is no approved medical therapy for hy-
pophosphatasia.1,5 Early, unsuccessful attempts to 
treat infantile hypophosphatasia with repeated 
intravenous infusions of soluble alkaline phos-
phatases14,15,21 suggested that TNSALP must be 
within the skeletal matrix to mineralize cartilage 
and bone.15 Avoiding extraskeletal excesses of al-
kaline phosphatase seemed important because di-
minished extracellular production of inorganic 
pyrophosphate causes generalized arterial calci-
fication of infancy.34 For life-threatening hypo-
phosphatasia, attempts to transplant cells derived 
from healthy mesenchyme to form TNSALP-replete 
osteoblasts appeared to benefit, but not cure, two 
girls with infantile hypophosphatasia.16,17 In case 
reports,35 teriparatide (parathyroid hormone ami-
no acid 1-34), which stimulates the biosynthesis of 
TNSALP in osteoblasts, appeared to be beneficial 
in some adults with hypophosphatasia.1
In this study, we found that bone-targeted en-
zyme replacement with ENB-0040 was effective in 
infants and young children with life-threatening 
or severely debilitating hypophosphatasia. Of the 
A B18 Months of Age (baseline) 32 Months of Age
Figure 3. Radiographic Findings in Patient 4.
A baseline radiograph shows generalized osteopenia of the chest but little 
deformity (Panel A). Consent for treatment was withdrawn during the initial 
intravenous infusion of ENB-0040, and the patient received no further 
treatment. A radiograph obtained 14 months after withdrawal shows sub-
stantial skeletal deterioration (Panel B).
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nine patients who were treated for at least 1 year, 
four had perinatal hypophosphatasia and five had 
infantile hypophosphatasia. One had lost nearly 
all radiographically apparent skeletal mineral dur-
ing prolonged ventilation and immobilization but 
still had a positive response to ENB-0040 therapy. 
Serum calcium levels were generally high at di-
agnosis (unlike calcium levels in other forms of 
rickets)1,5 and initially required dietary calcium 
restriction in all patients, most of whom had 
nephrocalcinosis.
Skeletal remineralization occurred during treat-
ment, without symptomatic hypocalcemia from 
calcium-avid bones, and was often accompanied 
by increases in serum parathyroid hormone levels 
that called for liberalization of dietary calcium 
but not additional vitamin D. A positive mineral 
balance throughout the skeleton was obvious on 
radiography after several weeks or months of 
treatment, and both membranous and endo-
chondral bone healed in most patients, with 
amelioration of nearly all complications of hypo-
phosphatasia. Substantial radiographic improve-
ment in skeletal abnormalities was noted at week 
24 in all but one patient, with continued healing 
through week 48. In the one patient who had no 
radiographically visible mineral at baseline, cal-
cification was observed after 9 months of thera-
py. This delay probably reflected the profound 
deficit of skeletal mineral in the patient, although 
sufficient hydroxyapatite was apparently present 
for targeting with ENB-0040. After the start of 
therapy, deciduous teeth erupted in all the pa-
tients, with only one patient having hypophos-
phatasia-related loss of a tooth.
Although the pathogenesis is not understood,1,5 
hypophosphatasia causes weakness, seemingly 
from a static myopathy.36 Improvement in venti-
latory function and in fine and gross motor skills 
was observed in all the patients in our study. 
Muscle weakness, hyperphosphatemia, and osteo-
malacia that are reminiscent of hypophosphata-
sia occur with toxic doses of the first-generation 
bisphosphonate, etidronate (a synthetic analogue 
of inorganic pyrophosphate),37,38 suggesting that 
an accumulation of inorganic pyrophosphate in 
hypophosphatasia may have a myopathic effect. It 
is possible that the improved motor function in our 
patients reflected hydrolysis of inorganic pyro-
phosphate or some as-yet-unrecognized TNSALP 
substrate.39
Although treatment with ENB-0040 markedly 
increased serum alkaline phosphatase levels in our 
patients, we found no evidence that it led to ec-
topic mineralization. We were concerned that 
subcutaneous injections of ENB-0040 might pre-
cipitate calcium and phosphate locally, because 
especially high levels of alkaline phosphatase 
would be present transiently near fibrillar col-
lagen,40 but this was not observed. Despite the 
presence of calcification in the kidneys of eight 
patients at baseline, no new occurrences of neph-
rocalcinosis were reported, and nephrocalcinosis 
resolved in one patient. Perhaps this finding re-
flected a reduction, but not overcorrection, of 
extracellular concentrations of inorganic pyro-
phosphate mirrored by plasma PLP levels that 
approached or achieved the normal range. Cra-
Table 2. Serious Adverse Events during the Treatment Period.*
Event
0–6 Months  
of Treatment
(N = 11)
7–12 Months  
of Treatment
(N = 10)
Events Patients Events Patients
no. no. (%) no. no. (%)
Total serious adverse events 31 7 (64) 27 8 (80)
Infection 9 5 (45) 8 5 (50)
Pneumonia 3 2 (18) 2 2 (20)
Tracheitis 0 0 2 2 (20)
Respiratory, thoracic, or mediastinal  
disorder
10 4 (36) 7 3 (30)
Respiratory distress 4 2 (18) 0 0
Respiratory failure 2 2 (18) 2 1 (10)
Nervous-system disorder 3 3 (27) 2 2 (20)
Convulsion 2 2 (18) 0 0
Increased intracranial pressure 1 1 (9) 2 2 (20)
General disorder or administration- 
site condition
2 2 (18) 0 0
Decreased oxygen saturation 2 2 (18) 0 0
Musculoskeletal or connective-tissue 
disorder — craniosynostosis
2 2 (18) 5 4 (40)
Surgical or medical procedure 0 0 2 2 (20)
* “Total serious adverse events” includes all serious adverse events, regardless 
of the incidence. Multiple events could occur in a single patient. The following 
serious adverse events occurred with a frequency of 10% or less during the 
treatment period and are not listed in the table: gastroenteritis (salmonella), 
hepatitis, H1N1 influenza, lower respiratory tract infection (viral), pneumonia 
due to respiratory syncytial virus, bronchiolitis due to respiratory syncytial vi-
rus, sepsis, asthma, dyspnea, hypoxemia, obstructive airway disorder, restric-
tive pulmonary disease, respiratory insufficiency, chronic disease of tonsils 
and adenoids, catheter-related complication, pyrexia, scoliosis, tachycardia, 
craniosynostosis, collapse of lung, craniectomy, gastrostomy-tube placement, 
bilateral conductive hearing loss, and renal stones. For complete data, see 
Table 5 in the Supplementary Appendix.
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niosynostosis and skull dysmorphology occur in 
approximately 40% of infants with hypophospha-
tasia.18 A similar percentage of our patients had 
craniosynostosis, suggesting that treatment with 
ENB-0040 does not alter its natural history.
In conclusion, ENB-0040, a recombinant hu-
man TNSALP coupled to a deca-aspartate motif 
for bone targeting, was administered by one in-
travenous infusion and then subcutaneous injec-
tions in children with perinatal or infantile hypo-
phosphatasia. Treatment was associated with 
healing of the skeletal manifestations of hypo-
phosphatasia as well as improved respiratory and 
motor function. Improvement is still being ob-
served in the patients receiving continued ENB-
0040 therapy, with more than 3 years of treat-
ment in some children. ENB-0040 appears to be a 
potential enzyme-replacement therapy in patients 
with life-threatening hypophosphatasia, a meta-
bolic bone disease.
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